how glp 1 drugs work Trends in the Development of GLP-1 Receptor Agonists GLP-1 Weight Loss Drugs: How

doi: 10.1016/0014-5793(91)80182-3

[DOI] [PubMed] [Google Scholar] 91.A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

Table 2 Clinical studies elucidating the use of antidiabetics against glaucoma

Through these studies, potential new opportunities have risen to utilize GLP-1 receptor agonists to treat nonalcoholic fatty liver disease (NAFLD), Parkinson disease, Alzheimer disease, osteoarthritis, and chemical dependency

ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)

It had more weight loss and glucose-lowering, although researchers didnt use the highest dose of semaglutide when comparing the two